Reata Pharmaceut Stock Price, News & Analysis

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced it will report its financial results and update on development programs pre-market on May 6, 2021. A conference call will be held the same day at 8:30 am ET, accessible by phone or via webcast. Financial results will be shared in an earnings press release available on Reata's website prior to the call. The audio of the call will be accessible for 90 days post-event. Reata focuses on developing therapeutics targeting metabolic and inflammatory pathways, with key candidates being bardoxolone methyl and omaveloxolone, which are still investigational.

Reata Pharmaceuticals announced the acceptance of its New Drug Application for bardoxolone methyl by the FDA to treat chronic kidney disease caused by Alport syndrome. Approximately 30,000-60,000 patients in the U.S. are affected, and if approved, bardoxolone will be the first therapy available for this condition. The PDUFA date is set for February 25, 2022. Data from the CARDINAL Phase 3 trial indicated significant improvements in kidney function, and bardoxolone showed a favorable safety profile.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced the appointment of Christy J. Oliger and Shamim Ruff to its Board of Directors, effective April 15, 2021. CEO Warren Huff expressed optimism about their experience as the company prepares for the commercial launch of bardoxolone methyl for treating chronic kidney disease due to Alport syndrome. Oliger has nearly 30 years in biopharmaceuticals, while Ruff has extensive regulatory experience. Both are expected to contribute significantly to advancing Reata's innovative therapies.

Reata Pharmaceuticals (Nasdaq: RETA) announced the presentation of clinical data for bardoxolone methyl at two nephrology conferences. The World Congress of Nephrology 2021 will feature an interim analysis of the EAGLE trial focusing on chronic kidney disease due to Alport syndrome. The ERA-EDTA Congress will present pediatric data from the Phase 3 CARDINAL trial. Bardoxolone, an investigational drug, is recognized for its therapeutic potential in CKD and has received Orphan Drug designation from the FDA and European Commission for Alport syndrome treatment.

Reata Pharmaceuticals (Nasdaq: RETA) announced its first NDA submission for bardoxolone in Alport syndrome, backed by Phase 3 trial data. This breakthrough potentially positions bardoxolone as the first approved treatment for CKD due to Alport syndrome. The company reported a solid cash balance of $818.2 million at year-end 2020, ensuring a funding runway through mid-2024. Key trial updates include over 220 patients enrolled in the FALCON trial for ADPKD and the initiation of the MERLIN trial for CKD. Financial results show a GAAP net loss decrease to $247.8 million for 2020.

Reata Pharmaceuticals (Nasdaq: RETA) announced the submission of a New Drug Application (NDA) for bardoxolone methyl to the FDA for treating chronic kidney disease caused by Alport syndrome. The NDA is based on data from the Phase 3 CARDINAL trial, which showed a significant improvement in kidney function over placebo. A request for Priority Review has been made, potentially accelerating the review process to eight months. If approved, bardoxolone would be the first therapy specifically for CKD due to Alport syndrome, addressing a critical need among patients.

Reata Pharmaceuticals (Nasdaq: RETA) will report its fourth quarter and full year 2020 financial results on March 1, 2021, before market open. A conference call is scheduled for the same day at 8:30 am ET, accessible by phone or via webcast. The earnings press release will be available on Reata's website shortly before the call and will remain accessible for one year. Reata develops innovative therapies targeting serious diseases by focusing on cellular metabolism and inflammation. Its lead candidates are bardoxolone methyl and omaveloxolone, which are investigational drugs.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) announced the successful closing of its public offering of 2,000,000 shares of Class A common stock at $140.85 per share, generating gross proceeds of $281.7 million. The underwriters also received a 30-day option to buy an additional 300,000 shares. Barclays Capital and Goldman Sachs served as joint book-running managers for the offering. The securities were offered under an effective shelf registration statement, with details filed with the SEC. Reata develops innovative therapeutics targeting serious diseases.

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) has priced a public offering of 2,000,000 shares of its Class A common stock at $140.85 per share, yielding gross proceeds of $281.7 million. The offering includes a 30-day option for underwriters to purchase an additional 300,000 shares. The offering is subject to customary closing conditions and is expected to conclude on December 4, 2020. Barclays Capital Inc. and Goldman Sachs & Co. LLC are acting as joint book-running managers for this offering.